Chemometec As Stock Probability Of Bankruptcy
| CHEMM Stock | DKK 480.80 5.00 1.03% |
ChemoMetec |
ChemoMetec AS Company probability of distress Analysis
ChemoMetec's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current ChemoMetec Probability Of Bankruptcy | Less than 9% |
Most of ChemoMetec's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ChemoMetec AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of ChemoMetec probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting ChemoMetec odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of ChemoMetec AS financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, ChemoMetec AS has a Probability Of Bankruptcy of 9.0%. This is 77.76% lower than that of the Life Sciences Tools & Services sector and 74.15% lower than that of the Health Care industry. The probability of bankruptcy for all Denmark stocks is 77.4% higher than that of the company.
ChemoMetec Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ChemoMetec's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ChemoMetec could also be used in its relative valuation, which is a method of valuing ChemoMetec by comparing valuation metrics of similar companies.ChemoMetec is currently under evaluation in probability of bankruptcy category among its peers.
ChemoMetec Fundamentals
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 | |||
| Profit Margin | 0.39 % | |||
| Operating Margin | 0.50 % | |||
| Current Valuation | 14.38 B | |||
| Shares Outstanding | 17.4 M | |||
| Shares Owned By Insiders | 10.87 % | |||
| Shares Owned By Institutions | 51.35 % | |||
| Price To Earning | 197.96 X | |||
| Price To Book | 40.83 X | |||
| Price To Sales | 32.10 X | |||
| Revenue | 428.39 M | |||
| Gross Profit | 384.25 M | |||
| EBITDA | 224.86 M | |||
| Net Income | 159.47 M | |||
| Cash And Equivalents | 209.02 M | |||
| Cash Per Share | 12.01 X | |||
| Total Debt | 6.79 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 2.57 X | |||
| Book Value Per Share | 26.27 X | |||
| Cash Flow From Operations | 176.86 M | |||
| Earnings Per Share | 10.15 X | |||
| Target Price | 1000.0 | |||
| Number Of Employees | 162 | |||
| Beta | 1.37 | |||
| Market Capitalization | 8.48 B | |||
| Total Asset | 501.27 M | |||
| Retained Earnings | 36 M | |||
| Working Capital | 25 M | |||
| Current Asset | 33 M | |||
| Current Liabilities | 8 M | |||
| Annual Yield | 0 % | |||
| Net Asset | 501.27 M |
About ChemoMetec Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ChemoMetec AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ChemoMetec using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ChemoMetec AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ChemoMetec
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoMetec position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoMetec will appreciate offsetting losses from the drop in the long position's value.Moving against ChemoMetec Stock
The ability to find closely correlated positions to ChemoMetec could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoMetec when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoMetec - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoMetec AS to buy it.
The correlation of ChemoMetec is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoMetec moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoMetec AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoMetec can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in ChemoMetec Stock
ChemoMetec financial ratios help investors to determine whether ChemoMetec Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ChemoMetec with respect to the benefits of owning ChemoMetec security.